IMPACT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK IN PATIENTS TREATED WITH UPADACITINIB VERSUS COMPARATORS: POST HOC ANALYSIS OF THE SELECT RHEUMATOID ARTHRITIS PROGRAM

被引：0

作者：

Charles-Schoeman, C. ^{[1
]}

Buch, M. H. ^{[2
,3
]}

Burmester, G. R. ^{[4
]}

Liu, J. ^{[5
]}

Dilley, D. ^{[5
]}

Palac, H. ^{[5
]}

Strengholt, S. ^{[5
]}

Curtis, J. ^{[6
]}

机构：

[1] Univ Calif Los Angeles, Div Rheumatol, Dept Med, Los Angeles, CA USA

[2] Univ Manchester, Manchester, Lancs, England

[3] NIHR Manchester Biomed Res Ctr, Ctr Musculoskeletal Res, Fac Biol Med & Hlth, Manchester, Lancs, England

[4] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany

[5] AbbVie, Immunol, N Chicago, IL USA

[6] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Safety; Targeted synthetic drugs; Cardiovascular disease;

D O I：

10.1136/annrheumdis-2023-eular.3337

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0828

引用

页码：711 / 712

页数：2

共 50 条

[31] IMPACT OF UPADACITINIB VERSUS ABATACEPT ON INDIVIDUAL DISEASE OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSES TO BIOLOGIC DMARDS
Van Vollenhoven, R.
Rubbert-Roth, A.
Hall, S.
Xavier, R.
Shmagel, A.
Song, Y.
Anyanwu, S.
Strand, V.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 626 - 626
[32] Impact of Upadacitinib Versus Abatacept on Individual Disease Outcomes in Patients With Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
Van Vollenhoven, Ronald
Rubbert-Roth, Andrea
Hall, Stephen
Xavier, Ricardo M.
Shmagel, Anna
Song, Yanna
Anyanwu, Samuel I.
Strand, Vibeke
SWISS MEDICAL WEEKLY, 2022, 152 : 14S - 14S
[33] Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk
Ahmed, Saba
Jacob, Benna
Carsons, Steven E.
De Leon, Joshua
Reiss, Allison B.
PHARMACEUTICALS, 2022, 15 (01)
[34] The management of cardiovascular disease risk in patients with rheumatoid arthritis
Ahmed, Omar
Krishnamurthy, Vinodh
Kaba, Riyaz A.
Tahir, Hasan
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (08) : 947 - 958
[35] RISK FACTORS FOR CARDIOVASCULAR DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS
van Halm, V. P.
Voskuyl, A. E.
Lems, W. F.
Steen, K. S.
Dijkmans, B. A.
RHEUMATOLOGY, 2002, 41 : 70 - 70
[36] Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis
Buch, Maya
Gomez-Puerta, Jose A.
Burmester, Gerd
Combe, Bernard G.
Rajendran, Vijay
Stiers, Pieter-Jan
Van Hoek, Paul
Van Beneden, Katrien
Gottenberg, Jacques-Eric
Tanaka, Yoshiya
Aletaha, Daniel
Westhovens, Rene
Caporali, Roberto F.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 875 - 877
[37] Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials
Wright, Grace
Mysler, Eduardo
Navarro-Millan, Iris
Tanaka, Yoshiya
Anyanwu, Samuel
Liu, Jianzhong
Tanjinatus, Oishi
Garrison, Andrew
Wells, Alvin
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 548 - 550
[38] PREVENT and Pooled Cohort Equations in Atherosclerotic Cardiovascular Disease Risk Prediction: A Post Hoc Analysis of SPRINT
Shetty, Naman S.
Gaonkar, Mokshad
Patel, Nirav
Vekariya, Nehal
Li, Peng
Arora, Garima
Arora, Pankaj
MAYO CLINIC PROCEEDINGS, 2025, 100 (02) : 384 - 387
[39] Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Ozen, Gulsen
Pedro, Sofia
Schumacher, Rebecca
Simon, Teresa
Michaud, Kaleb
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[40] Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors
Cavalli, Giulio
Favalli, Ennio Giulio
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6

← 1 2 3 4 5 →